Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial.
Amita Patnaik
No relevant relationships to disclose
Patricia LoRusso
Research Funding - Astellas Pharma
Howard A. Ball
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
Erkut Bahceci
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
Geoffrey Yuen
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
Kyriakos P. Papadopoulos
Research Funding - Astellas Pharma
Muaiad Kittaneh
Research Funding - Astellas Pharma
Anthony W. Tolcher
Research Funding - Astellas Pharma